(Q35157038)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Developing inhibitors of the epidermal growth factor receptor for cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

Viktor Grünwald

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

851-867

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12813169%20AND%20SRC:MED&resulttype=core&format=json

Cell signaling by receptor tyrosine kinases

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Disulfide bond structure of human epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The single transmembrane domains of ErbB receptors self-associate in cell membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

SH2 and PTB domain interactions in tyrosine kinase signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Signal transduction by the JNK group of MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The target of rapamycin (TOR) proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The role of radiation therapy in the treatment of head and neck cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Multinomial phase II cancer trials incorporating response and early progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851

Molecular ticket to enter cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F95.12.851